IL-NIQ
10.7.2024 15:01:35 CEST | Business Wire | Press release
NielsenIQ (NIQ) today announced the launch of an integrated user experience for its Consumer Panel clients globally. This brings the Full View of Retail measurement and Consumer Panel data to life on a single platform, NIQ Discover. With a focus on elevating the client experience, the Discover platform leverages a new cloud-based architecture and aggregation engine providing faster data accessibility and user flexibility.
NIQ's Discover platform for Consumer Panel is set to transform the consumer insights landscape. With its advanced analytical models and always-on capabilities, NIQ is leading the way in delivering actionable insights. Clients can now enjoy a modern and intuitive interface that enhances their interaction with the platform, opening endless possibilities to analyze consumer behaviors to drive growth. “NIQ has made significant investments in our global consumer panel capabilities in the past year, enhancing performance, quality and usability of data driven insights. The launch of this modern, cloud-based platform is one of several enhancements we are making to our Consumer Panel offerings globally. Clients will now get access to panel data together with retail measurement, delivering a connected user experience,” said Kris Ewing, President, Global Consumer Panel Services, NIQ.
Key benefits of NIQ Discover platform for Consumer Panel include:
- Elevated user experience: On-demand insights unlocked through an intuitive and powerful visualization experience, side-by-side with retail measurement data, enabling seamless, guided flows that cross complementary data sets.
- Flexibility: Clients can build their own analyses and get results on-the-fly, opening a world of possibilities across different dimensions of people groups, facts, products, retailers, geographies, periods and demographics.
- On-demand Data: Access to advanced analytical models elevates the data analysis experience seamlessly within seconds. Clients can access key performance indicators like penetration in addition to more sophisticated analytical models like Super Shifting, Key Item Ranking, Assortment Optimizer and Portfolio Trial and Repeat
- Gen AI-driven insights through NIQ Ask Arthur: Consumer panel on NIQ Discover enables users to leverage NIQ Ask Arthur, a groundbreaking Gen AI-driven tool, to aid in global search, streamline data analysis and facilitate informed decision-making.
NIQ’s Consumer Panel Services (CPS) provides the most complete and clear view of today’s consumers across 23 markets. Some of the enhancements NIQ is making to its Consumer Panel include:
- Expansion of panel sample sizes globally, with broader coverage and representation across North America, West Europe, and Pacific.
- The best data: Delivering the Full View of consumer behavior across retail channels and brands with panel quality and coverage the industry trusts.
- Expanded analytical capacity through industry-leading consumer experts who bring powerful insights to life, connecting NIQ’s Retail Measurement data, Consumer Panel and other NIQ offerings to drive growth for CPG and retailer clients.
NIQ Discover for CPS provides an unparalleled user experience, delivering the best quality, the widest coverage, and most sophisticated analytics all in a single platform. It redefines the way clients can harness the analytical power of NIQ data and elevate insights to unprecedented heights.
About NIQ
NielsenIQ (NIQ) is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. NIQ combined with GfK in 2023, bringing together the two industry leaders with unparalleled global reach. Today NIQ has operations in more than 95 countries covering 97% of GDP. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710255063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom